Hossein Pakdaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hossein Pakdaman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Akram Esfandani
Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication- Ali Amini Harandi
Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Farshid Alaeddini
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Ghazaleh Goudarzi
Department of Brain and Cognitive Sciences, Cell Science Research Center Royan Institute for Stem Cell Biology and Technology, ACECR Tehran Iran
1 shared publication - Hadi Kazemi
School of Built Environment and Engineering, Leeds Beckett University
1 shared publication - Koorosh Shahpasand
Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
1 shared publication
Latest Publications
- 15 February 2022
- Published by Wiley in Journal of Neuroscience Research
- Vol. 100 (4) , 1084-1104
Tau nuclear translocation is a leading step in tau pathology process through P53 stabilization and nucleolar dispersion
Tau protein abnormalities are associated with various neurodegenerative disorders, including Alzheimer's disease (AD) and traumatic brain injury (TBI). In tau‐overexpressing SHSY5Y cells and iPSC‐derived neuron models of frontotemporal dementia (FTD), axonal tau translocates into the nuclear compartment, resulting in neuronal dysfunction. Despite extensive research, the mechanisms by which tau translocation results in neurodegeneration remain elusive thus far. We studied the nuclear displacement of different P‐tau species [Cis phosphorylated Thr231‐tau (cis P‐tau), phosphorylated Ser202/Thr205‐tau (AT8 P‐tau), and phosphorylated Thr212/Ser214‐tau (AT100 P‐tau)] at various time points using starvation in primary cortical neurons and single severe TBI (ssTBI) in male mouse cerebral cortices as tauopathy models. While all P‐tau species translocated into the somatodendritic compartment in response to stress, cis P‐tau did so more rapidly than the other species. Notably, nuclear localization of P‐tau was associated with p53 apoptotic stabilization and nucleolar stress, both of which resulted in neurodegeneration. In summary, our findings indicate that P‐tau nuclear translocation results in p53‐dependent apoptosis and nucleolar dispersion, which is consistent with neurodegeneration.
- 15 February 2022
- Published by Wiley in Journal of Neuroscience Research
- Vol. 100 (4) , 1084-1104
Tau nuclear translocation is a leading step in tau pathology process through P53 stabilization and nucleolar dispersion
Tau protein abnormalities are associated with various neurodegenerative disorders, including Alzheimer's disease (AD) and traumatic brain injury (TBI). In tau‐overexpressing SHSY5Y cells and iPSC‐derived neuron models of frontotemporal dementia (FTD), axonal tau translocates into the nuclear compartment, resulting in neuronal dysfunction. Despite extensive research, the mechanisms by which tau translocation results in neurodegeneration remain elusive thus far. We studied the nuclear displacement of different P‐tau species [Cis phosphorylated Thr231‐tau (cis P‐tau), phosphorylated Ser202/Thr205‐tau (AT8 P‐tau), and phosphorylated Thr212/Ser214‐tau (AT100 P‐tau)] at various time points using starvation in primary cortical neurons and single severe TBI (ssTBI) in male mouse cerebral cortices as tauopathy models. While all P‐tau species translocated into the somatodendritic compartment in response to stress, cis P‐tau did so more rapidly than the other species. Notably, nuclear localization of P‐tau was associated with p53 apoptotic stabilization and nucleolar stress, both of which resulted in neurodegeneration. In summary, our findings indicate that P‐tau nuclear translocation results in p53‐dependent apoptosis and nucleolar dispersion, which is consistent with neurodegeneration.
- Open Access
- 30 October 2021
- Published by Maad Rayan Publishing Company in International Clinical Neuroscience Journal
- Vol. 8 (4) , 208-211
Migraine Headache as a Presenting Feature of Multiple Sclerosis: A Case Report
Multiple sclerosis (MS) is a chronic inflammatory disease, causing neuronal demyelination and axonal damage in the central nervous system. Symptoms of MS vary widely because of different grades of sensory, motor, and cognitive dysfunctions. Although headache as the initial symptom of MS is rare, it is a common comorbidity that affects most patients. However, it is unclear that the headache manifestation in newly diagnosed people with MS should be considered as an MS attack or merely a comorbid condition. We report the case of a 31-year-old woman with newly diagnosed MS who presented with exacerbation of headache episodes without any abnormal neurological exam findings. The headaches did not respond to nonsteroidal anti-inflammatory drugs and triptans. After administration of methylprednisolone, the headaches were significantly improved, and during 3 months of follow-up receiving glatiramer acetate, no episode of headache has occurred. This case demonstrates the possible relationship between migraine and MS in newly diagnosed patients. New-onset headaches, a change in the pattern of previous episodes, and inadequate clinical drug response to headache treatment should all be taken seriously and warrant further investigation. Thereby, early diagnosis and proper treatment for patients with MS could improve their quality of life.
- 30 October 2021
- Published by Maad Rayan Publishing Company in International Clinical Neuroscience Journal
- Vol. 8 (4) , 208-211
Open AccessMigraine Headache as a Presenting Feature of Multiple Sclerosis: A Case Report
Multiple sclerosis (MS) is a chronic inflammatory disease, causing neuronal demyelination and axonal damage in the central nervous system. Symptoms of MS vary widely because of different grades of sensory, motor, and cognitive dysfunctions. Although headache as the initial symptom of MS is rare, it is a common comorbidity that affects most patients. However, it is unclear that the headache manifestation in newly diagnosed people with MS should be considered as an MS attack or merely a comorbid condition. We report the case of a 31-year-old woman with newly diagnosed MS who presented with exacerbation of headache episodes without any abnormal neurological exam findings. The headaches did not respond to nonsteroidal anti-inflammatory drugs and triptans. After administration of methylprednisolone, the headaches were significantly improved, and during 3 months of follow-up receiving glatiramer acetate, no episode of headache has occurred. This case demonstrates the possible relationship between migraine and MS in newly diagnosed patients. New-onset headaches, a change in the pattern of previous episodes, and inadequate clinical drug response to headache treatment should all be taken seriously and warrant further investigation. Thereby, early diagnosis and proper treatment for patients with MS could improve their quality of life.
- Open Access
- 3 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Epilepsy lifetime prevalence in Iran: a large population- based national survey
Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.
- 3 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessEpilepsy lifetime prevalence in Iran: a large population- based national survey
Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.